Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Dynamic Business Location.

Hookipa: EUR 50 million for immunotherapy against cancer

© Hookipa Biotech

A vaccination against the Cytomegalovirus ("CMV"), which is a herpesvirus, should be tested on patients undergoing organ transplants. In addition, immunization therapy is to be tested on patients with head and neck squamous cell carcinoma. Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

Austria Map

Find the perfect location for your company

Austria stands out due to its long-term reliable and stable conditions. These
features are particularly important for a research-based company such as
Boehringer Ingelheim. Furthermore, Vienna is a city with a good research
infrastructure and a high quality of life, and is thus also an interesting place
for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

PwC study: Five publicly-listed Austrian companies among the top 1,000 in R&D

The 1,000 largest publicly listed companies have never invested as much in research and development as they did in 2018.

Where does data live?

In the age of digitalization, success depends on one simple question: “Where and how do you process your data?” In our data-driven world, the decisive issue in ensuring that your company remains part of the value chain is how you handle your data. Here you will find out why different types of data require different strategies, and what you can learn from the plans of leading decision makers.

More news All blog posts